Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 36,800 shares, an increase of 1,500.0% from the December 31st total of 2,300 shares. Based on an average daily volume of 214,500 shares, the short-interest ratio is presently 0.2 days.

Chugai Pharmaceutical Trading Down 1.5 %

OTCMKTS:CHGCY opened at $20.33 on Thursday. The company has a market cap of $66.91 billion, a PE ratio of 26.06 and a beta of 0.81. Chugai Pharmaceutical has a twelve month low of $14.52 and a twelve month high of $26.00. The company’s 50 day moving average is $21.62 and its two-hundred day moving average is $22.45.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.